yahoo_financeOriginal article
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
RegulatoryPelareorepPositive
AI Analysis
Summary
Oncolytics Biotech received Fast Track Designation from the FDA for Pelareorep in second-line and later anal cancer, expediting the development and review process for this therapeutic candidate.
Outcome Details
Fast Track Designation granted
Importance:6/10
Sentiment:
0.70
Fast Track DesignationPelareorepAnal CancerRegulatory ApprovalOncolytics Biotech
Related Companies
Read the original article
Published by yahoo_finance on July 20, 2026 1:00 PM